Efficacy of Transcutaneous Auricular Trigeminal Nerve Stimulation in Migraine: A Randomized, Participant- and Assessor-Blinded, Sham-Controlled Trial.

Migraine is a common and disabling condition affecting many people globally. Researchers studied a new treatment called transcutaneous auricular trigeminal nerve stimulation (taTNS). This method is non-invasive and targets pain pathways in the head. The study involved 102 participants who were randomly assigned to receive either active taTNS or a sham treatment. The active treatment was given three times a week for 12 weeks. Researchers measured migraine pain intensity, disability, sleep quality, and heart rate variability. Results showed that taTNS significantly reduced migraine pain intensity and improved sleep quality. Participants receiving taTNS experienced less disability related to migraines compared to those receiving the sham treatment. This suggests that taTNS could be a helpful option for managing migraines. Overall, this research highlights the potential benefits of taTNS as a new treatment for migraine sufferers. Clinical relevance: This research indicates that taTNS may effectively reduce migraine pain and improve sleep quality, offering a promising new treatment option for patients.